Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | VNN1 | O95497 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658651 | 0.87 | SPR (0.55) | SPRVNN1 | |
| SCHEMBL8241804 | 0.84 | KCNH2 (0.67) | MEN1KMT2AAPOBEC3AAPOBEC3GKCNH2 | |
| SCHEMBL19658664 | 0.83 | EPHX2 (0.56) | SPRMEN1KMT2AVNN1 | |
| SCHEMBL22317619 | 0.82 | CYP3A4 (0.52) | SPRVNN1 | |
| SCHEMBL19226476 | 0.81 | ALDH1A1 (0.53) | SPRMEN1KMT2AVNN1 | |
| SCHEMBL12255642 | 0.80 | HRH3 (0.52) | MEN1KMT2AKCNH2HRH3CHRM1 | |
| SCHEMBL17888365 | 0.79 | ALDH1A1 (0.68) | SPRMEN1KMT2AVNN1 | |
| SCHEMBL13873252 | 0.79 | FAAH (0.49) | SPRMEN1KMT2APOLBVNN1 | |
| SCHEMBL2280397 | 0.79 | GPR119 (0.61) | SPR | |
| SCHEMBL17886758 | 0.79 | ALDH1A1 (0.54) | MEN1KMT2AVNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135552-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | SENTINEL ONCOLOGY LIMITED (GB) | 2022-05-05 | — | — | US | disclosed |
| US-10258603-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10258603-B2 | Therapeutic compounds and uses thereof | BRD4, BRDT, BRD3 | SPR 607/4885MEN1 1364/4885KMT2A 165/4885 |
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | SPR 607/4885MEN1 1364/4885KMT2A 165/4885 |
| US-20220135552-A1 | PYRROLE DERIVATIVES AS PLK1 INHIBITORS | PLK1, CDK1, AURKC | SPR 708/4885MEN1 2744/4885KMT2A 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.